Founded at the Abramson Cancer Center at the University of Pennsylvania

Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial

Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial

JAMA Oncology │ 2018

Chandrajit P. Raut; N. Joseph Espat; Robert G. Maki; Dejka M. Araujo; Jonathan Trent; Toni Faith Williams; D. Das Purkayastha; Ronald P. DeMatteo